W.e.f. 04 November 2018
Suven Life Sciences announced that the company is participating and presenting positive Pre-clinical and Phase-1 clinical data of several advanced molecules from heir portfolio of new chemical entities (NCEs) and the status of Phase 2 clinical trial of their lead compound SUVN-502 at Neuroscience 2018, organized by Society for Neuroscience being held at San Diego, USA during 4 to 7 November 2018. Suven Life Science is a biopharma company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in CNS therapies using GPCR targets. Suven has 4 clinical stage compounds, a Phase 2 undergoing SUVN-502, Phase 2 ready SUVN-G3031, and Phase1 completed SUVN-D4010 and SUVN-911.Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
